use of tumor markers in testicular, prostate, colorectal, breast, and ...
use of tumor markers in testicular, prostate, colorectal, breast, and ...
use of tumor markers in testicular, prostate, colorectal, breast, and ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
74 Use <strong>of</strong> Tumor Markers <strong>in</strong> Testicular, Prostate, Colorectal, Breast, <strong>and</strong> Ovarian Cancers<br />
435. MRC Cl<strong>in</strong>ical Trials Unit: OV05 Cl<strong>in</strong>ical Trial. http://www.<br />
ctu.mrc.ac.uk/studies/OV05.asp (Accessed 20th October 2007).<br />
436. Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention,<br />
diagnosis, <strong>and</strong> treatment. CA Cancer J Cl<strong>in</strong> 1999;49:297–320.<br />
437. Vermorken JB, Avall-Lundqvist E, Pfisterer J, Bacon M. The<br />
Gynecologic Cancer Intergroup (GCIG): history <strong>and</strong> current status.<br />
Ann Oncol 2005;16 Suppl 8:viii39–viii42.<br />
438. Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL,<br />
2nd, Armstrong DK, Bristow RE. Risk <strong>of</strong> epithelial ovarian cancer<br />
recurrence <strong>in</strong> patients with ris<strong>in</strong>g serum CA-125 levels<br />
with<strong>in</strong> the normal range. J Cl<strong>in</strong> Oncol 2005;23:9338–9343.<br />
439. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI,<br />
Anderson B, Buller RE. Preoperative CA 125 levels: an <strong>in</strong>dependent<br />
prognostic factor for epithelial ovarian cancer. Obstet<br />
Gynecol 2002;100:59–64.<br />
440. Gadducci A, Cosio S, Fanucchi A, Negri S, Crist<strong>of</strong>ani R,<br />
Genazzani AR. The predictive <strong>and</strong> prognostic value <strong>of</strong> serum<br />
CA 125 half-life dur<strong>in</strong>g paclitaxel/plat<strong>in</strong>um-based chemotherapy<br />
<strong>in</strong> patients with advanced ovarian carc<strong>in</strong>oma. Gynecol Oncol<br />
2004;93:131–136.<br />
441. Rust<strong>in</strong> GJ. The cl<strong>in</strong>ical value <strong>of</strong> tumour <strong>markers</strong> <strong>in</strong> the management<br />
<strong>of</strong> ovarian cancer. Ann Cl<strong>in</strong> Biochem 1996;33 (Pt<br />
4):284–289.<br />
442. Fayers PM, Rust<strong>in</strong> G, Wood R, Nelstrop A, Leonard RC,<br />
Wilk<strong>in</strong>son P, et al. The prognostic value <strong>of</strong> serum CA 125 <strong>in</strong><br />
patients with advanced ovarian carc<strong>in</strong>oma: an analysis <strong>of</strong> 573<br />
patients by the Medical Research Council Work<strong>in</strong>g Party on<br />
Gynaecological Cancer. Int J Gynecol Cancer 1993;3:285–292.<br />
443. Verheijen RH, von Mensdorff-Pouilly S, van Kamp GJ,<br />
Kenemans P. CA 125: fundamental <strong>and</strong> cl<strong>in</strong>ical aspects. Sem<strong>in</strong><br />
Cancer Biol 1999;9:117–124.<br />
444. Ried<strong>in</strong>ger JM, Wafflart J, Ricolleau G, Eche N, Larbre H,<br />
Basuyau JP, et al. CA 125 half-life <strong>and</strong> CA 125 nadir dur<strong>in</strong>g<br />
<strong>in</strong>duction chemotherapy are <strong>in</strong>dependent predictors <strong>of</strong> epithelial<br />
ovarian cancer outcome: results <strong>of</strong> a French multicentric study.<br />
Ann Oncol 2006;17:1234–1238.<br />
445. Diam<strong>and</strong>is EP, Yo<strong>use</strong>f GM. Human tissue kallikre<strong>in</strong>s: a family<br />
<strong>of</strong> new cancer bio<strong>markers</strong>. Cl<strong>in</strong> Chem 2002;48:1198–1205.<br />
446. Diam<strong>and</strong>is EP, Yo<strong>use</strong>f GM, Soosaipillai AR, Bunt<strong>in</strong>g P. Human<br />
kallikre<strong>in</strong> 6 (zyme/protease M/neuros<strong>in</strong>): a new serum biomarker<br />
<strong>of</strong> ovarian carc<strong>in</strong>oma. Cl<strong>in</strong> Biochem 2000;33:579–583.<br />
447. H<strong>of</strong>fman BR, Katsaros D, Scorilas A, Diam<strong>and</strong>is P, Fracchioli<br />
S, Rigault de la Longrais IA, et al. Immun<strong>of</strong>luorometric quantitation<br />
<strong>and</strong> histochemical localisation <strong>of</strong> kallikre<strong>in</strong> 6 prote<strong>in</strong> <strong>in</strong><br />
ovarian cancer tissue: a new <strong>in</strong>dependent unfavourable prognostic<br />
biomarker. Br J Cancer 2002;87:763–771.<br />
448. Diam<strong>and</strong>is EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass<br />
L, et al. Human kallikre<strong>in</strong> 11: a new biomarker <strong>of</strong> <strong>prostate</strong> <strong>and</strong><br />
ovarian carc<strong>in</strong>oma. Cancer Res 2002;62:295–300.<br />
449. Dong Y, Kaushal A, Bui L, Chu S, Fuller PJ, Nickl<strong>in</strong> J, et al.<br />
Human kallikre<strong>in</strong> 4 (KLK4) is highly expressed <strong>in</strong> serous ovarian<br />
carc<strong>in</strong>omas. Cl<strong>in</strong> Cancer Res 2001;7:2363–2371.<br />
450. Obiezu CV, Scorilas A, Katsaros D, Massobrio M, Yo<strong>use</strong>f GM,<br />
Fracchioli S, et al. Higher human kallikre<strong>in</strong> gene 4 (KLK4)<br />
expression <strong>in</strong>dicates poor prognosis <strong>of</strong> ovarian cancer patients.<br />
Cl<strong>in</strong> Cancer Res 2001;7:2380–2386.<br />
451. Kim H, Scorilas A, Katsaros D, Yo<strong>use</strong>f GM, Massobrio M,<br />
Fracchioli S, et al. Human kallikre<strong>in</strong> gene 5 (KLK5) expression<br />
is an <strong>in</strong>dicator <strong>of</strong> poor prognosis <strong>in</strong> ovarian cancer. Br J Cancer<br />
2001;84:643–650.<br />
452. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yo<strong>use</strong>f GM,<br />
Fracchioli S, et al. The human KLK8 (neurops<strong>in</strong>/ovas<strong>in</strong>) gene:<br />
identification <strong>of</strong> two novel splice variants <strong>and</strong> its prognostic<br />
value <strong>in</strong> ovarian cancer. Cl<strong>in</strong> Cancer Res 2001;7:806–811.<br />
453. Chang A, Yo<strong>use</strong>f GM, Jung K, Rajpert-De ME, Diam<strong>and</strong>is EP.<br />
Identification <strong>and</strong> molecular characterization <strong>of</strong> five novel<br />
kallikre<strong>in</strong> gene 13 (KLK13; KLK-L4) splice variants: differential<br />
expression <strong>in</strong> the human testis <strong>and</strong> <strong>testicular</strong> cancer.<br />
Anticancer Res 2001;21:3147–3152.<br />
454. Yo<strong>use</strong>f GM, Scorilas A, Katsaros D, Fracchioli S, Isk<strong>and</strong>er L,<br />
Borgono C, et al. Prognostic value <strong>of</strong> the human kallikre<strong>in</strong><br />
gene 15 expression <strong>in</strong> ovarian cancer. J Cl<strong>in</strong> Oncol 2003;21:<br />
3119–3126.<br />
455. Borgono CA, Grass L, Soosaipillai A, Yo<strong>use</strong>f GM, Petraki CD,<br />
Howarth DH, et al. Human kallikre<strong>in</strong> 14: a new potential biomarker<br />
for ovarian <strong>and</strong> <strong>breast</strong> cancer. Cancer Res 2003;63:9032–9041.<br />
456. Yo<strong>use</strong>f GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC,<br />
Scorilas A, et al. Human kallikre<strong>in</strong> 5: a potential novel serum<br />
biomarker for <strong>breast</strong> <strong>and</strong> ovarian cancer. Cancer Res 2003;<br />
63:3958–3965.<br />
457. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N,<br />
Schmalfeldt B, et al. Human kallikre<strong>in</strong> 8, a novel biomarker for<br />
ovarian carc<strong>in</strong>oma. Cancer Res 2003;63:2771–2774.<br />
458. Diam<strong>and</strong>is EP, Scorilas A, Fracchioli S, Van GM, De BH, Henrik<br />
A, et al. Human kallikre<strong>in</strong> 6 (hK6): a new potential serum biomarker<br />
for diagnosis <strong>and</strong> prognosis <strong>of</strong> ovarian carc<strong>in</strong>oma. J Cl<strong>in</strong><br />
Oncol 2003;21:1035–1043.<br />
459. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bell<strong>in</strong>o R, Van<br />
GM, et al. The serum concentration <strong>of</strong> human kallikre<strong>in</strong> 10 represents<br />
a novel biomarker for ovarian cancer diagnosis <strong>and</strong> prognosis.<br />
Cancer Res 2003;63:807–811.<br />
460. Yo<strong>use</strong>f GM, Polymeris ME,Yacoub GM, Scorilas A, Soosaipillai<br />
A, Popalis C, et al. Parallel overexpression <strong>of</strong> seven kallikre<strong>in</strong><br />
genes <strong>in</strong> ovarian cancer. Cancer Res 2003;63:2223–2227.<br />
461. Kurlender L, Yo<strong>use</strong>f GM, Memari N, Robb JD, Michael IP,<br />
Borgono C, et al. Differential expression <strong>of</strong> a human kallikre<strong>in</strong><br />
5 (KLK5) splice variant <strong>in</strong> ovarian <strong>and</strong> <strong>prostate</strong> cancer. Tumour<br />
Biol 2004;25:149–156.<br />
462. Diam<strong>and</strong>is EP, Borgono CA, Scorilas A, Harbeck N, Dorn J,<br />
Schmitt M. Human kallikre<strong>in</strong> 11: an <strong>in</strong>dicator <strong>of</strong> favorable<br />
prognosis <strong>in</strong> ovarian cancer patients. Cl<strong>in</strong> Biochem 2004;<br />
37:823–829.<br />
463. Scorilas A, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B,<br />
Schmitt M, Diam<strong>and</strong>is EP. Human kallikre<strong>in</strong> 13 prote<strong>in</strong> <strong>in</strong> ovarian<br />
cancer cytosols: a new favorable prognostic marker. J Cl<strong>in</strong><br />
Oncol 2004;22:678–685.<br />
464. Kyriakopoulou LG, Yo<strong>use</strong>f GM, Scorilas A, Katsaros D,<br />
Massobrio M, Fracchioli S, Diam<strong>and</strong>is EP. Prognostic value <strong>of</strong><br />
quantitatively assessed KLK7 expression <strong>in</strong> ovarian cancer. Cl<strong>in</strong><br />
Biochem 2003;36:135–143.<br />
465. Yo<strong>use</strong>f GM, Kyriakopoulou LG, Scorilas A, Fracchioli S,<br />
Ghir<strong>in</strong>ghello B, Zarghooni M, et al. Quantitative expression <strong>of</strong><br />
the human kallikre<strong>in</strong> gene 9 (KLK9) <strong>in</strong> ovarian cancer: a new<br />
<strong>in</strong>dependent <strong>and</strong> favorable prognostic marker. Cancer Res<br />
2001;61:7811–7818.<br />
466. Luo LY, Bunt<strong>in</strong>g P, Scorilas A, Diam<strong>and</strong>is EP. Human kallikre<strong>in</strong><br />
10: a novel <strong>tumor</strong> marker for ovarian carc<strong>in</strong>oma? Cl<strong>in</strong> Chim<br />
Acta 2001;306:111–118.<br />
467. Shih Ie M, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth<br />
C, et al. Ovarian cancer specific kallikre<strong>in</strong> pr<strong>of</strong>ile <strong>in</strong> effusions.<br />
Gynecol Oncol 2007;105:501–507.<br />
468. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate<br />
CM, et al. Osteopont<strong>in</strong> as a potential diagnostic biomarker for<br />
ovarian cancer. JAMA 2002;287:1671–1679.
Change language